Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for neurodegenerative diseases, has announced it will host a corporate update webinar on September 2, 2026, at 4 p.m. EDT. The webinar will feature founder, president, and CEO Maria Maccecchini, Ph.D., who will discuss recent progress, ongoing clinical programs, and upcoming milestones. This announcement is significant for investors and patients alike, as it provides a clear timeline for the company's lead candidate, buntanetap, which is being evaluated for Alzheimer's disease (AD) and Parkinson's disease (PD).
The company has fully enrolled its pivotal Phase 3 AD trial, with top-line data and regulatory submissions expected in 2027. This milestone is crucial because buntanetap targets multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing the underlying causes of neurodegeneration, buntanetap aims to halt disease progression and improve cognitive and motor functions, offering a potential disease-modifying therapy for millions affected by these debilitating conditions.
In addition to the Phase 3 trial, Annovis plans to begin enrolling patients in an AD open-label study in October 2026 to generate long-term safety data. The PD open-label study is already underway, and discussions are ongoing regarding the initiation of a Parkinson's disease dementia program. These initiatives are designed to provide comprehensive data on buntanetap's safety and efficacy, which are essential for regulatory approval and eventual clinical adoption.
The webinar will include a live question-and-answer session, providing an opportunity for stakeholders to gain deeper insights into the company's strategies and expectations. This transparency is vital for building investor confidence and for the broader medical community to understand the potential impact of buntanetap.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to developing treatments for neurodegenerative diseases. The company's focus on a single oral therapy that addresses multiple toxic proteins could represent a paradigm shift in how these diseases are treated. As the company progresses toward key data readouts, the outcomes of these trials will not only determine the future of buntanetap but also offer hope for patients who currently have limited treatment options.
For more information about the webinar and to access the full press release, interested parties can visit this link. To stay updated on the latest news and developments from Annovis Bio, visit the company's newsroom at https://ibn.fm/ANVS.
